CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate...
Phase 1, Phase 2
Saint Louis, Missouri, United States and 8 other locations
pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate...
Phase 1
Saint Louis, Missouri, United States and 15 other locations
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate...
Phase 3
Saint Louis, Missouri, United States and 21 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Saint Louis, Missouri, United States and 107 other locations
Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate...
Phase 3
Saint Louis, Missouri, United States and 16 other locations
Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...
Phase 1
Saint Louis, Missouri, United States and 16 other locations
This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic...
Saint Louis, Missouri, United States
to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate...
Phase 4
Saint Louis, Missouri, United States and 1 other location
This is a phase 1 study to assess the safety and tolerability of ARX517 in adult subjects with Metastatic Castration-Resistant Prostate Cancer...
Phase 1
Saint Louis, Missouri, United States and 8 other locations
period of time (for a maximum of 2 years (32 cycles) or until radiographic progression) on the treatment of castrate-resistant, metastatic prostate...
Phase 2
Saint Louis, Missouri, United States and 1 other location
Clinical trials
Research sites
Resources
Legal